COVID-19 UPDATE Contact BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more information on access to our products, please call our customer service line at 1-800-469-0261. NEWS: BDSI Completes Acquisition of ELYXYB™ Learn More > INSPIRING SOLUTIONS FOR BETTER HEALTH BDSI advances novel therapies designed to improve the lives of people living with serious and debilitating chronic conditions Hear from the Experts Dr. Jessica Ailani and Dr. Peter McAllister share their views on ELYXYB™ (celecoxib) oral solution, the first and only FDA-approved treatment of its kind. Watch now Purpose BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company working to deliver innovative therapies for individuals living with serious and debilitating chronic conditions. Learn more Patients BDSI subscribes to a patients-first philosophy. We are a dynamic team driven by the knowledge that the work we do can have a positive impact on patients, their caretakers, and loved ones. Learn more Products BDSI offers a diverse portfolio of solutions for the treatment of serious and debilitating chronic conditions, including unique therapeutic innovations like a buccal film technology designed to help optimize drug delivery. Learn more Recent BDSI News November 3, 2021 Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential Read more October 21, 2021 RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Read more October 20, 2021 RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of Read more More news Upcoming Events There are no events to display More events Stay Connected Stay up to date on the latest news Get started now November 24, 2021BDSI $3.001/ - -0.96% Data provided by Nasdaq. Minimum 15 minutes delayed. Company Products Science & Education Investors Careers Copyright © 2021 | BioDelivery Sciences International, Inc. Terms & Conditions | Privacy Policy